Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Prepares Ground For Deployment Of COVID-19 Vaccines

Plans Include Vaccination Priorities, Safety Studies And Tackling Mistrust

Executive Summary

With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.

You may also be interested in...



Coronavirus Notebook: Pfizer/BioNTech & Russian Vaccines Each Claim Efficacy Of More than 90%

As data start to come in on the first coronavirus vaccines, hopes are rising that vaccination campaigns will be able to begin in the next month or two, although experts have cautioned against unbridled optimism. Uncertainties also remain over questions such as whom to vaccinate first and how to assure equitable access in less wealthy parts of the world.

Pressure Group Undaunted By EU Refusal To Disclose COVID-19 Vaccine Contracts

The European Commission has dismissed attempts by pressure groups to secure access to details of COVID-19 vaccine deals negotiated with pharmaceutical firms. The Corporate Europe Observatory says it is “disappointed” by the decision but is not giving up the chase.

Coronavirus Notebook: EU Strikes Deals For Gilead’s Veklury, Janssen’s Vaccine

Russia is planning to register a second COVID-19 vaccine this month, while the UK is ramping up its manufacturing capacity for vaccines and therapeutics. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel